Merck Research Laboratories. "We are particularly thrilled to share research from the Phase 3 ZENITH trial evaluating WINREVAIR in PAH as a late-breaking presentation. ZENITH is the first study in ...

Merck Research Laboratories. “We are particularly thrilled to share research from the Phase 3 ZENITH trial evaluating WINREVAIR in PAH as a late-breaking presentation. ZENITH is the first study ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

By Sriparna Roy (Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S ...

president of Merck Research Laboratories, said: ““We are deeply grateful to the researchers and patients who participated in the anacetrapib clinical development programme, and in particular ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio-metabolic ...

president of Merck Research Laboratories. "We continue to augment our oncology pipeline and look forward to working with the Kelun-Biotech team to advance these candidates to the patients that ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...